Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

Science Translational Medicine

Volumn 9, Issue 374, 2017, Pages

  DeVos, Sarah L ^a   Miller, Rebecca L ^a   Schoch, Kathleen M ^a   Holmes, Brandon B ^a   Kebodeaux, Carey S ^a   Wegener, Amy J ^a   Chen, Guo ^a   Shen, Tao ^a   Tran, Hien ^a   Nichols, Brandon ^b   Zanardi, Tom A ^b   Kordasiewicz, Holly B ^b   Swayze, Eric E ^b   Bennett, C Frank ^b   Diamond, Marc I ^c   Miller, Timothy M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; TAU PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; EMBRYO; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PARALYSIS; PROTEIN EXPRESSION; TAUOPATHY; ALZHEIMER DISEASE; ANIMAL; BRAIN; CEREBROSPINAL FLUID; DISEASE MODEL; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MACACA FASCICULARIS; MICE; MICE, TRANSGENIC; NEURONS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 85011390798     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag0481     Document Type: Article

References (66)

1. H. Braak, E. Braak, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
2. B. T. Hyman, G. W. Van Hoesen, A. R. Damasio, C. L. Barnes, Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170 (1984).
3. P. T. Nelson, I. Alafuzoff, E. H. Bigio, C. Bouras, H. Braak, N. J. Cairns, R. J. Castellani, B. J. Crain, P. Davies, K. Del Tredici, C. Duyckaerts, M. P. Frosch, V. Haroutunian, P. R. Hof, C. M. Hulette, B. T. Hyman, T. Iwatsubo, K. A. Jellinger, G. A. Jicha, E. Kövari, W. A. Kukull, J. B. Leverenz, S. Love, I. R. Mackenzie, D. M. Mann, E. Masliah, A. C. McKee, T. J. Montine, J. C. Morris, J. A. Schneider, J. A. Sonnen, D. R. Thal, J. Q. Trojanowski, J. C. Troncoso, T. Wisniewski, R. L. Woltjer, T. G. Beach, Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381 (2012).
4. M. Hosokawa, T. Arai, M. Masuda-Suzukake, T. Nonaka, M. Yamashita, H. Akiyama, M. Hasegawa, Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLOS ONE 7, e52389 (2012).
5. S.-W. Min, X. Chen, T. E. Tracy, Y. Li, Y. Zhou, C. Wang, K. Shirakawa, S. S. Minami, E. Defensor, S. A. Mok, P. D. Sohn, B. Schilling, X. Cong, L. Ellerby, B. W. Gibson, J. Johnson, N. Krogan, M. Shamloo, J. Gestwicki, E. Masliah, E. Verdin, L. Gan, Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154-1162 (2015).
6. N. Myeku, C. L. Clelland, S. Emrani, N. V. Kukushkin, W. H. Yu, A. L. Goldberg, K. E. Duff, Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat. Med. 22, 46-53 (2016).
7. K. Yanamandra, N. Kfoury, H. Jiang, T. E. Mahan, S. Ma, S. E. Maloney, D. F. Wozniak, M. I. Diamond, D. M. Holtzman, Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414 (2013).
8. D. L. Castillo-Carranza, U. Sengupta, M. J. Guerrero-Muñoz, C. A. Lasagna-Reeves, J. E. Gerson, G. Singh, D. M. Estes, A. D. T. Barrett, K. T. Dineley, G. R. Jackson, R. Kayed, Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci.34, 4260-4272 (2014).
9. M. Bi, A. Ittner, Y. D. Ke, J. Götz, L. M. Ittner, Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLOS ONE 6, e26860 (2011).
10. M. Boimel, N. Grigoriadis, A. Lourbopoulos, E. Haber, O. Abramsky, H. Rosenmann, Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472-485 (2010).
11. A. Ittner, J. Bertz, L. S. Suh, C. H. Stevens, J. Götz, L. M. Ittner, Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J. Neurochem. 132, 135-145 (2015).
12. P. Lei, S. Ayton, D. I. Finkelstein, L. Spoerri, G. D. Ciccotosto, D. K. Wright, B. X. W. Wong, P. A. Adlard, R. A. Cherny, L. Q. Lam, B. R. Roberts, I. Volitakis, G. F. Egan, C. A. McLean, R. Cappai, J. A. Duce, A. I. Bush, Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291-295 (2012).
13. M. Morris, P. Hamto, A. Adame, N. Devidze, E. Masliah, L. Mucke, Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol. Aging 34, 1523-1529 (2013).
14. Z. Li, A. M. Hall, M. Kelinske, E. D. Roberson, Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol. Aging 35, 2617-2624 (2014).
15. S. L. DeVos, D. K. Goncharoff, G. Chen, C. S. Kebodeaux, K. Yamada, F. R. Stewart, D. R. Schuler, S. E. Maloney, D. F. Wozniak, F. Rigo, C. F. Bennett, J. R. Cirrito, D. M. Holtzman, T. M. Miller, Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887-12897 (2013).
16. R. A. Smith, T. M. Miller, K. Yamanaka, B. P. Monia, T. P. Condon, G. Hung, C. S. Lobsiger, C. M. Ward, M. McAlonis-Downes, H. Wei, E. V. Wancewicz, C. F. Bennett, D. W. Cleveland, Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290-2296 (2006).
17. H. B. Kordasiewicz, L. M. Stanek, E. V. Wancewicz, C. Mazur, M. M. McAlonis, K. A. Pytel, J. W. Artates, A. Weiss, S. H. Cheng, L. S. Shihabuddin, G. Hung, C. F. Bennett, D. W. Cleveland, Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044 (2012).
18. K. M. Schoch, S. L. DeVos, R. L. Miller, S. J. Chun, M. Norrbom, D. F. Wozniak, H. N. Dawson, C. F. Bennett, F. Rigo, T. M. Miller, Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 90, 941-947 (2016).
19. C. Lagier-Tourenne, M. Baughn, F. Rigo, S. Sun, P. Liu, H.-R. Li, J. Jiang, A. T. Watt, S. Chun, M. Katz, J. Qiu, Y. Sun, S.-C. Ling, Q. Zhu, M. Polymenidou, K. Drenner, J. W. Artates, M. McAlonis-Downes, S. Markmiller, K. R. Hutt, D. P. Pizzo, J. Cady, M. B. Harms, R. H. Baloh, S. R. Vandenberg, G. W. Yeo, X.-D. Fu, C. F. Bennett, D. W. Cleveland, J. Ravits, Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A. 110, E4530-E4539 (2013).
20. C. J. Donnelly, P.-W. Zhang, J. T. Pham, A. R. Haeusler, A. R. Heusler, N. A. Mistry, S. Vidensky, E. L. Daley, E. M. Poth, B. Hoover, D. M. Fines, N. Maragakis, P. J. Tienari, L. Petrucelli, B. J. Traynor, J. Wang, F. Rigo, C. F. Bennett, S. Blackshaw, R. Sattler, J. D. Rothstein, RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415-428 (2013).
21. T. M. Miller, A. Pestronk, W. David, J. Rothstein, E. Simpson, S. H. Appel, P. L. Andres, K. Mahoney, P. Allred, K. Alexander, L. W. Ostrow, D. Schoenfeld, E. A. Macklin, D. A. Norris, G. Manousakis, M. Crisp, R. Smith, C. F. Bennett, K. M. Bishop, M. E. Cudkowicz, An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435-442 (2013).
22. Y. Yoshiyama, M. Higuchi, B. Zhang, S.-M. Huang, N. Iwata, T. C. Saido, J. Maeda, T. Suhara, J. Q. Trojanowski, V. M.-Y. Lee, Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351 (2007).
23. Y.-J. Lee, S. B. Han, S.-Y. Nam, K.-W. Oh, J. T. Hong, Inflammation and Alzheimer's disease. Arch. Pharm. Res. 33, 1539-1556 (2010).
24. T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, M. G. Tansey, Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 4, 47 (2009).
25. A. Saul, F. Sprenger, T. A. Bayer, O. Wirths, Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. Neurobiol .Aging 34, 2564-2573 (2013).
26. B. B. Holmes, S. L. DeVos, N. Kfoury, M. Li, R. Jacks, K. Yanamandra, M. O. Ouidja, F. M. Brodsky, J. Marasa, D. P. Bagchi, P. T. Kotzbauer, T. M. Miller, D. Papy-Garcia, M. I. Diamond, Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U.S.A. 110, E3138-E3147 (2013).
27. A. de Calignon, M. Polydoro, M. Suárez-Calvet, C. William, D. H. Adamowicz, K. J. Kopeikina, R. Pitstick, N. Sahara, K. H. Ashe, G. A. Carlson, T. L. Spires-Jones, B. T. Hyman, Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697 (2012).
28. L. Liu, V. Drouet, J. W. Wu, M. P. Witter, S. A. Small, C. Clelland, K. Duff, Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7, e31302 (2012).
29. L. C. Walker, M. I. Diamond, K. E. Duff, B. T. Hyman, Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 70, 304-310 (2013).
30. B. B. Holmes, J. L. Furman, T. E. Mahan, T. R. Yamasaki, H. Mirbaha, W. C. Eades, L. Belaygorod, N. J. Cairns, D. M. Holtzman, M. I. Diamond, Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. U.S.A. 111, E4376-E4385 (2014).
31. J. L. Furman, B. B. Holmes, M. I. Diamond, Sensitive detection of proteopathic seeding activity with FRET flow cytometry. J. Vis. Exp. e53205 (2015).
32. V. Torres-Lista, L. Giménez-Llort, Impairment of nesting behaviour in 3xTg-AD mice. Behav. Brain Res. 247, 153-157 (2013).
33. K. Yamada, J. K. Holth, F. Liao, F. R. Stewart, T. E. Mahan, H. Jiang, J. R. Cirrito, T. K. Patel, K. Hochgräfe, E.-M. Mandelkow, D. M. Holtzman, Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387-393 (2014).
34. A. Lleó, E. Cavedo, L. Parnetti, H. Vanderstichele, S. K. Herukka, N. Andreasen, R. Ghidoni, P. Lewczuk, A. Jeromin, B. Winblad, M. Tsolaki, B. Mroczko, P. J. Visser, I. Santana, P. Svenningsson, K. Blennow, D. Aarsland, J. L. Molinuevo, H. Zetterberg, B. Mollenhauer, Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat. Rev. Neurol. 11, 41-55 (2015).
35. M. Polydoro, A. de Calignon, M. Suárez-Calvet, L. Sanchez, K. R. Kay, S. B. Nicholls, A. D. Roe, R. Pitstick, G. A. Carlson, T. Gómez-Isla, T. L. Spires-Jones, B. T. Hyman, Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. J. Neurosci. 33, 13300-13311 (2013).
36. K. Santacruz, J. Lewis, T. Spires, J. Paulson, L. Kotilinek, M. Ingelsson, A. Guimaraes, M. DeTure, M. Ramsden, E. McGowan, C. Forster, M. Yue, J. Orne, C. Janus, A. Mariash, M. Kuskowski, B. Hyman, M. Hutton, K. H. Ashe, Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
37. M. Dumont, C. Stack, C. Elipenahli, S. Jainuddin, M. Gerges, N. N. Starkova, L. Yang, A. A. Starkov, F. Beal, Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 25, 4063-4072 (2011).
38. H. Takeuchi, M. Iba, H. Inoue, M. Higuchi, K. Takao, K. Tsukita, Y. Karatsu, Y. Iwamoto, T. Miyakawa, T. Suhara, J. Q. Trojanowski, V. M.-Y. Lee, R. Takahashi, P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLOS ONE 6, e21050 (2011).
39. G. R. Mallucci, M. D. White, M. Farmer, A. Dickinson, H. Khatun, A. D. Powell, S. Brandner, J. G. R. Jefferys, J. Collinge, Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53, 325-335 (2007).
40. G. U. Höglinger, N. M. Melhem, D. W. Dickson, P. M. A. Sleiman, L.-S. Wang, L. Klei, R. Rademakers, R. de Silva, I. Litvan, D. E. Riley, J. C. van Swieten, P. Heutink, Z. K. Wszolek, R. J. Uitti, J. Vandrovcova, H. I. Hurtig, R. G. Gross, W. Maetzler, S. Goldwurm, E. Tolosa, B. Borroni, P. Pastor; PSP Genetics Study Group, L. B. Cantwell, M. R. Han, A. Dillman, M. P. van der Brug, J. R. Gibbs, M. R. Cookson, D. G. Hernandez, A. B. Singleton, M. J. Farrer, C.-E. Yu, L. I. Golbe, T. Revesz, J. Hardy, A. J. Lees, B. Devlin, H. Hakonarson, U. Müller, G. D. Schellenberg, Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699-705 (2011).
41. A. L. Boxer, A. E. Lang, M. Grossman, D. S. Knopman, B. L. Miller, L. S. Schneider, R. S. Doody, A. Lees, L. I. Golbe, D. R. Williams, J.-C. Corvol, A. Ludolph, D. Burn, S. Lorenzl, I. Litvan, E. D. Roberson, G. U. Höglinger, M. Koestler, C. R. Jack Jr., V. Van Deerlin, C. Randolph, I. V Lobach, H. W. Heuer, I. Gozes, L. Parker, S. Whitaker, J. Hirman, A. J. Stewart, M. Gold, B. H. Morimoto; AL-108-231 Investigators, Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet. Neurol. 13, 676-685 (2014).
42. J. C. Rojas, A. L. Boxer, Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation. Nat. Rev. Neurol. 12, 74-76 (2016).
43. M. Goedert, B. Ghetti, M. G. Spillantini, Frontotemporal dementia: Implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006254 (2012).
44. D. T. Chien, S. Bahri, A. K. Szardenings, J. C. Walsh, F. Mu, M.-Y. Su, W. R. Shankle, A. Elizarov, H. C. Kolb, Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457-468 (2013).
45. I. Santa-Maria, A. Haggiagi, X. Liu, J. Wasserscheid, P. T. Nelson, K. Dewar, L. N. Clark, J. F. Crary, The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 124, 693-704 (2012).
46. C. Cruchaga, J. S. K. Kauwe, O. Harari, S. C. Jin, Y. Cai, C. M. Karch, B. A. Benitez, A. T. Jeng, T. Skorupa, D. Carrell, S. Bertelsen, M. Bailey, D. McKean, J. M. Shulman, P. L. De Jager, L. Chibnik, D. A. Bennett, S. E. Arnold, D. Harold, R. Sims, A. Gerrish, J. Williams, V. M. Van Deerlin, V. M.-Y. Lee, L. M. Shaw, J. Q. Trojanowski, J. L. Haines, R. Mayeux, M. A. Pericak-Vance, L. A. Farrer, G. D. Schellenberg, E. R. Peskind, D. Galasko, A. M. Fagan, D. M. Holtzman, J. C. Morris; GERAD Consortium, Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer Disease Genetic Consortium (ADGC), A. M. Goate, GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 78, 256-268 (2013).
47. R. S. Desikan, A. J. Schork, Y. Wang, A. Witoelar, M. Sharma, L. K. McEvoy, D. Holland, J. B. Brewer, C.-H. Chen, W. K. Thompson, D. Harold, J. Williams, M. J. Owen, M. C. O'Donovan, M. A. Pericak-Vance, R. Mayeux, J. L. Haines, L. A. Farrer, G. D. Schellenberg, P. Heutink, A. B. Singleton, A. Brice, N. W. Wood, J. Hardy, M. Martinez, S. H. Choi, A. DeStefano, M. A. Ikram, J. C. Bis, A. Smith, A. L. Fitzpatrick, L. Launer, C. van Duijn, S. Seshadri, I. D. Ulstein, D. Aarsland, T. Fladby, S. Djurovic, B. T. Hyman, J. Snaedal, H. Stefansson, K. Stefansson, T. Gasser, O. A. Andreassen, A. M. Dale; ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators, Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol. Psychiatry 20, 1588-1595 (2015).
48. Y. Zhao, I.-C. Tseng, C. J. Heyser, E. Rockenstein, M. Mante, A. Adame, Q. Zheng, T. Huang, X. Wang, P. E. Arslan, P. Chakrabarty, C. Wu, G. Bu, W. C. Mobley, Y.-w. Zhang, P. St George-Hyslop, E. Masliah, P. Fraser, H. Xu, Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron 87, 963-975 (2015).
49. A. Kondo, K. Shahpasand, R. Mannix, J. Qiu, J. Moncaster, C.-H. Chen, Y. Yao, Y.-M. Lin, J. A. Driver, Y. Sun, S. Wei, M.-L. Luo, O. Albayram, P. Huang, A. Rotenberg, A. Ryo, L. E. Goldstein, A. Pascual-Leone, A. C. McKee, W. Meehan, X. Z. Zhou, K. P. Lu, Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523, 431-436 (2015).
50. E. D. Roberson, K. Scearce-Levie, J. J. Palop, F. Yan, I. H. Cheng, T. Wu, H. Gerstein, G.-Q. Yu, L. Mucke, Reducing endogenous tau ameliorates amyloid b-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007).
51. E. D. Roberson, B. Halabisky, J. W. Yoo, J. Yao, J. Chin, F. Yan, T. Wu, P. Hamto, N. Devidze, G.-Q. Yu, J. J. Palop, J. L. Noebels, L. Mucke, Amyloid-b/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711 (2011).
52. K. A. Vossel, K. Zhang, J. Brodbeck, A. C. Daub, P. Sharma, S. Finkbeiner, B. Cui, L. Mucke, Tau reduction prevents Ab-induced defects in axonal transport. Science 330, 198 (2010).
53. K. Leroy, K. Ando, V. Laporte, R. Dedecker, V. Suain, M. Authelet, C. Héraud, N. Pierrot, Z. Yilmaz, J.-N. Octave, J.-P. Brion, Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol. 181, 1928-1940 (2012).
54. L. M. Ittner, Y. D. Ke, F. Delerue, M. Bi, A. Gladbach, J. van Eersel, H. Wölfing, B. C. Chieng, M. J. Christie, I. A. Napier, A. Eckert, M. Staufenbiel, E. Hardeman, J. Götz, Dendritic function of tau mediates amyloid-b toxicity in Alzheimer's disease mouse models. Cell 142, 387-397 (2010).
55. E. Suberbielle, P. E. Sanchez, A. V. Kravitz, X. Wang, K. Ho, K. Eilertson, N. Devidze, A. C. Kreitzer, L. Mucke, Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-b. Nat. Neurosci. 16, 613-621 (2013).
56. A. van Hummel, M. Bi, S. Ippati, J. van der Hoven, A. Volkerling, W. S. Lee, D. C. S. Tan, A. Bongers, A. Ittner, Y. D. Ke, L. M. Ittner, No overt deficits in aged tau-deficient C57Bl/6.Mapttm1(EGFP)Kit GFP knockin mice. PLOS ONE 11, e0163236 (2016).
57. M. A. Passini, J. Bu, A. M. Richards, C. Kinnecom, S. P. Sardi, L. M. Stanek, Y. Hua, F. Rigo, J. Matson, G. Hung, E. M. Kaye, L. S. Shihabuddin, A. R. Krainer, C. F. Bennett, S. H. Cheng, Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18 (2011).
58. C. A. Chiriboga, K. J. Swoboda, B. T. Darras, S. T. Iannaccone, J. Montes, D. C. De Vivo, D. A. Norris, C. F. Bennett, K. M. Bishop, Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86, 890-897 (2016).
59. S. L. DeVos, T. M. Miller, Antisense oligonucleotides: Treating neurodegeneration at the level of RNA. Neurotherapeutics 10, 486-497 (2013).
60. R. A. McKay, L. J. Miraglia, L. L. Cummins, S. R. Owens, H. Sasmor, N. M. Dean, Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-a expression. J. Biol. Chem. 274, 1715-1722 (1999).
61. S. L. DeVos, T. M. Miller, Direct intraventricular delivery of drugs to the rodent central nervous system. J. Visualized Exp. e50326 (2013).
62. S. Wegmann, E. A. Maury, M. J. Kirk, L. Saqran, A. Roe, S. L. DeVos, S. Nicholls, Z. Fan, S. Takeda, O. Cagsal-Getkin, C. M. William, T. L. Spires-Jones, R. Pitstick, G. A. Carlson, A. M. Pooler, B. T. Hyman, Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J. 34, 3028-3041 (2015).
63. D. W. Sanders, S. K. Kaufman, S. L. DeVos, A. M. Sharma, H. Mirbaha, A. Li, S. J. Barker, A. C. Foley, J. R. Thorpe, L. C. Serpell, T. M. Miller, L. T. Grinberg, W. W. Seeley, M. I. Diamond, Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271-1288 (2014).
64. S. Takeda, S. Wegmann, H. Cho, S. L. DeVos, C. Commins, A. D. Roe, S. B. Nicholls, G. A. Carlson, R. Pitstick, C. K. Nobuhara, I. Costantino, M. P. Frosch, D. J. Müller, D. Irimia, B. T. Hyman, Neuronal uptake and propagation of a rare phosphorylated high-molecularweight tau derived from Alzheimer's disease brain. Nat. Commun. 6, 8490 (2015).
65. S. Takeda, C. Commins, S. L. DeVos, C. K. Nobuhara, S. Wegmann, A. D. Roe, I. Costantino, Z. Fan, S. B. Nicholls, A. E. Sherman, A. T. Trisini Lipsanopoulos, C. R. Scherzer, G. A. Carlson, R. Pitstick, E. R. Peskind, M. A. Raskind, G. Li, T. J. Montine, M. P. Frosch, B. T. Hyman, Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. Ann. Neurol. 80, 355-367 (2016).
66. R. Deacon, Assessing burrowing, nest construction, and hoarding in mice. J. Visualized Exp. 2012, e2607 (2012).